



Please type a plus sign inside this box +

PTO/SB/08B(05/03)

Approved for use through 05/31/2003, OMB 0651-0031

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Application Number	10/691,051
Filing Date	October 22, 2003
First Named Inventor	Seon
Group Art Unit	
Examiner Name	
Attorney Docket Number	03551.0137

Sheet	1	of	2
-------	---	----	---

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
BK	1	BUHRING et al. <i>Endoglin is expressed on a subpopulation of immature erythroid cells of normal human bone marrow.</i> Leukemia, 5: 841-847, 1991.	
	2	BURROWS et al. <i>Up-regulation of Endoglin on Vascular Endothelial Cells in Human Solid Tumors: Implications for Diagnosis and Therapy.</i> Clin. Cancer Res., 1: 1623-1634, 1995.	
	3	CHEIFETZ et al. <i>Endoglin is a component of the transforming growth factor-beta receptor system in human endothelial cells.</i> J. Biol. Chem., 267: 19027-19030, 1992.	
	4	FONSATTI et al. <i>Endoglin is a suitable target for efficient imaging of solid tumors: In vivo evidence in a canine mammary carcinoma model.</i> Clin. Cancer Res., 6: 2037-2043, 2000.	
	5	GOUGOS et al. <i>Identification of a human endothelial cell antigen with monoclonal antibody 44G4 produced against a pre-B leukemic cell line.</i> J. Immunol., 141: 1925-1933, 1988.	
	6	HARUTA et al. <i>Distinct human leukemia-associated cell surface glycoprotein GP160 defined by monoclonal antibody SN6.</i> Proc. Natl. Acad. Sci. U S A, 83: 7898-7902, 1986.	
	7	LASTRES et al. <i>Regulated expression on human macrophages of endoglin, an Arg-Gly-Asp- containing surface antigen.</i> Eur. J. Immunol., 22: 393-397, 1992.	
	8	LI et al. <i>Defective angiogenesis in mice lacking endoglin.</i> Science, 284: 1534-1537, 1999.	
	9	MATSUZAKI et al. <i>Effect of Induced Transformation of Human Leukemia Cells on the Expression of GP160, A Novel Human Leukemia-Associated Cell Surface Glycoprotein.</i> Fed. Proc. 46: 1056, 1987.	
	10	MATSUNO et al. <i>Induction of lasting complete regression of preformed distinct solid tumors by targeting the tumor vasculature using two new anti-endoglin monoclonal antibodies.</i> Clin. Cancer Res., 5: 371-382, 1999.	
BK	11	MILLER et al. <i>Elevated expression of endoglin, a component of the TGF-beta-receptor complex, correlates with proliferation of tumor endothelial cells.</i> Int. J. Cancer, 81: 568-572, 1999.	

Examiner Signature		Date Considered	7/11/05
--------------------	--	-----------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number. ² Applicant is to place a check mark here if English Translation is attached.

Burden Hour Statement: The form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. Send to the Commissioner for Patents, P.O. Box 1450, Alexandria, Virginia 22313-1450.



Please type a plus sign inside this box +

PTO/SB/08B(05/03)

Approved for use through 05/31/2003, OMB 0651-0031

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet	2	of	2	Application Number	10/691,051
				Filing Date	October 22, 2003
				First Named Inventor	Seon
				Group Art Unit	
				Examiner Name	
				Attorney Docket Number	03551.0137

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
8/6	12	ROKHLIN et al. <i>Differential expression of endoglin on fetal and adult hematopoietic cells in human bone marrow.</i> J. Immunol., 154: 4456-4465, 1995.	
	13	SEON et al. <i>CD105 Workshop: Immunohistochemical detection of CD105 in the vascular endothelium of human malignant and non-malignant tissues.</i> In: T. Kishimoto, H. Kikutani, A. E. G. Kr. Von dem Borne, S. Goyert, D. Mason, M. Miyasaka, L. Moretta, K. Okumura, S. Shaw, T. A. Springer, K. Sugamura, and H. Zola (eds.), <i>Leukocyte Typing VI: White Cell Differentiation Antigens</i> , pp. 709-710. New York: Garland Publishing, Inc., 1998.	
	14	SEON et al. <i>Long-lasting complete inhibition of human solid tumors in SCID mice by targeting endothelial cells of tumor vasculature with antihuman endoglin immunotoxin.</i> Clin. Cancer Res., 3: 1031-1044, 1997.	
	15	TABATA et al. <i>Antiangiogenic radioimmunotherapy of human solid tumors in SCID mice using ¹²⁵I-labeled anti-endoglin monoclonal antibodies.</i> Int. J. Cancer, 82: 737-742, 1999.	
8/6	16	WANG et al. <i>A monoclonal antibody detects heterogeneity in vascular endothelium of tumours and normal tissues.</i> Int. J. Cancer, 54: 363-370, 1993.	

Examiner Signature		Date Considered	4/11/05
--------------------	--	-----------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number. ² Applicant is to place a check mark here if English Translation is attached.

Burden Hour Statement: The form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. Send to the Commissioner for Patents, P.O. Box 1450, Alexandria, Virginia 22313-1450.